Abstract
Colonization of the stomach by Helicobacter pylori can result in such gastrointestinal illnesses as chronic gastritis, peptic ulcer and gastric cancer. Antimicrobial peptides (AMPs) are expressed in the stomach and play a key role in the innate immune responses to H. pylori in humans. During H. pylori infections, AMP expression mediated by NOD-1, NF-kB and/or ERK, functions to eradicate the bacteria, thereby preventing the gastritis and gastric cancer. This suggests that the use of synthetic AMPs could be one component of an effective therapeutic strategy to combat H. pylori. In addition, it appears that some peptides, and combinations of peptides, act synergistically with conventional drugs, thereby enhancing therapeutic efficacy. Our aim in this article was to review what is currently known about gastric AMP expression in response to H. pylori infection, and to briefly discuss the potential use of AMPs, either alone or in combination with conventional antibiotics, for the treatment of H. pylori infection.
Keywords: Antimicrobial peptides, gastrointestinal illnesses, Helicobacter pylori, synergy effect, therapeutic efficacy.
Protein & Peptide Letters
Title:Role of Antimicrobial Peptides Expressed by Host Cells Upon Infection by Helicobacter pylori
Volume: 21 Issue: 10
Author(s): Ramamourthy Gopal, Eunsil Jeong, Chang Ho Seo and Yoonkyung Park
Affiliation:
Keywords: Antimicrobial peptides, gastrointestinal illnesses, Helicobacter pylori, synergy effect, therapeutic efficacy.
Abstract: Colonization of the stomach by Helicobacter pylori can result in such gastrointestinal illnesses as chronic gastritis, peptic ulcer and gastric cancer. Antimicrobial peptides (AMPs) are expressed in the stomach and play a key role in the innate immune responses to H. pylori in humans. During H. pylori infections, AMP expression mediated by NOD-1, NF-kB and/or ERK, functions to eradicate the bacteria, thereby preventing the gastritis and gastric cancer. This suggests that the use of synthetic AMPs could be one component of an effective therapeutic strategy to combat H. pylori. In addition, it appears that some peptides, and combinations of peptides, act synergistically with conventional drugs, thereby enhancing therapeutic efficacy. Our aim in this article was to review what is currently known about gastric AMP expression in response to H. pylori infection, and to briefly discuss the potential use of AMPs, either alone or in combination with conventional antibiotics, for the treatment of H. pylori infection.
Export Options
About this article
Cite this article as:
Gopal Ramamourthy, Jeong Eunsil, Seo Ho Chang and Park Yoonkyung, Role of Antimicrobial Peptides Expressed by Host Cells Upon Infection by Helicobacter pylori, Protein & Peptide Letters 2014; 21 (10) . https://dx.doi.org/10.2174/0929866521666140708092032
DOI https://dx.doi.org/10.2174/0929866521666140708092032 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapy in Gastric Carcinoma: Current Status and Future Perspectives
Clinical Cancer Drugs Anti-obesity Effects of Some Plant Extracts in Rats Fed with High-Fat Diet
The Natural Products Journal An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials Translating Cancer Biomarker Discoveries to Clinical Tests: What should be Considered?
Recent Patents on Biomarkers Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Current Drug Metabolism Recent Advances in the Treatment of Interstitial Lung Disease in Patients with Polymyositis/Dermatomyositis
Endocrine, Metabolic & Immune Disorders - Drug Targets Determination of the Sodium Concentration in Brazilian Light and Non- Light Powdered Instant Soups by Flame Photometry
Current Nutrition & Food Science Pyrimidine Salvage Pathway in Mycobacterium tuberculosis
Current Medicinal Chemistry Correlations between Overexpression of SOX2OT Long Non-coding RNA and Susceptibility to Breast Cancer
Combinatorial Chemistry & High Throughput Screening Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases
Current Pharmaceutical Design Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Novel Therapeutic Approaches Based on the Targeting of Microenvironment-Derived Survival Pathways in Human Cancer: Experimental Models and Translational Issues
Current Pharmaceutical Design Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry MMP-2 Selectivity in Hydroxamate-Type Inhibitors
Current Medicinal Chemistry